about
Multivariable confounding adjustment in distributed data networks without sharing of patient-level data.Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs.An analytic framework for aligning observational and randomized trial data: Application to postmenopausal hormone therapy and coronary heart disease.Accuracy of Electronic Health Record-Derived Data for the Identification of Incident ADHD.Trends in elective labor induction for six United States health plans, 2001-2007.Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities.Trends in the use of antiepileptic drugs among pregnant women in the US, 2001-2007: a medication exposure in pregnancy risk evaluation program study.Trimethoprim-sulfonamide use during the first trimester of pregnancy and the risk of congenital anomaliesValidation of an algorithm to estimate gestational age in electronic health plan databases.Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585,615 deliveries.The prevalence and trends of antiviral medication use during pregnancy in the US: a population-based study of 664,297 deliveries in 2001-2007.A critical review of methods to evaluate the impact of FDA regulatory actions.Validation of claims-based algorithms for identification of high-grade cervical dysplasia and cervical cancer.Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort StudyPotential bias of instrumental variable analyses for observational comparative effectiveness research.Antiemetic use among pregnant women in the United States: the escalating use of ondansetron.Enrollment and Retention in 34 United States Pregnancy Registries Contrasted with the Manufacturer's Capture of Spontaneous Reports for Exposed Pregnancies.Stakeholders' views on data sharing in multicenter studies.Sentinel Modular Program for Propensity-Score Matched Cohort Analyses: Application to Glyburide, Glipizide, and Serious Hypoglycemia.Successful Comparison of US Food and Drug Administration Sentinel Analysis Tools to Traditional Approaches in Quantifying a Known Drug-Adverse Event Association.Use of selective serotonin reuptake inhibitors (SSRIs) in women delivering liveborn infants and other women of child-bearing age within the U.S. Food and Drug Administration's Mini-Sentinel program.Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database.The Impact of FDA Regulatory Activities on Incident Dispensing of LABA-Containing Medication: 2005-2011.Surveillance of Medication Use During Pregnancy in the Mini-Sentinel Program.Changing patterns of asthma medication use related to US Food and Drug Administration long-acting β2-agonist regulation from 2005-2011.Privacy-preserving analytic methods for multisite comparative effectiveness and patient-centered outcomes research.Big data in epidemiology: too big to fail?Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-Sentinel program.Chronic opioid use emerging after bariatric surgery.The National Patient-Centered Clinical Research Network (PCORnet) Bariatric Study Cohort: Rationale, Methods, and Baseline Characteristics.Comparative effectiveness of laparoscopic adjustable gastric banding vs laparoscopic gastric bypass.Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study.Trends in 30-day readmission rates after COPD hospitalization, 2006-2012.Safety assessment of niacin in the US Food and Drug Administration's mini-sentinel system.Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study.Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM.Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel System.Pharmacotherapy for incident attention-deficit/hyperactivity disorder: practice patterns and quality metrics.Evaluation of the US Food and Drug Administration sentinel analysis tools in confirming previously observed drug-outcome associations: The case of clindamycin and Clostridium difficile infection.Utilization of drugs with pregnancy exposure registries during pregnancy.
P50
Q30656746-4AB00060-27C2-43C1-8DFA-42A431756E81Q30660067-328AC219-D97D-4CCE-9D92-9036A9760F28Q30696956-27ED9CBA-0455-4641-9ADD-0202F3CC5856Q30752901-1A5CA669-90E8-4619-B5D7-758D2735BDD3Q34535001-AB585613-EC31-4A01-815F-BDA5F76F1FCFQ36253136-9B8DC3E1-485D-464D-A71E-1AB4664072A9Q36347356-2624774F-9717-41AE-8CC0-85586E7DBE27Q36635441-9CF3F8EB-B3A5-4C35-B68C-B364C4E12065Q36816458-F28BA66D-49DE-4F57-BBF2-33E71EA82314Q37026000-48A6363F-C838-468B-A615-0EB7DB81194CQ37179568-26838190-06B2-42B2-8105-A66A94C24544Q37301216-338A5B06-9B88-4FCD-80EB-69C874C959D0Q37374498-C47C0C72-44B4-4B3A-A9AC-B84EB7BE9B0CQ37527438-260A6880-C4FE-45AE-A079-A62373CC1FA3Q38229374-67F32A24-0423-4E9A-ACA1-3BF52EE47243Q38402567-562A3862-38EA-4ABA-8329-6EE2FF6C98B1Q38608711-0DC53EA3-D03B-458F-9EC2-3CFC61029644Q38626241-3CB8063A-0A4E-47E5-95AC-A7914DF20A89Q38691096-9FCB9671-9DA4-45F3-BA40-C18A6F9B1987Q39602398-A7B42336-4932-4FA8-9008-872ACB164352Q39767363-9102C6EC-009B-4C86-8127-7B9F7B369B3AQ39794572-97A222F0-38E1-43FA-A4C4-9D7AAFC1341BQ40041139-DCDC784A-B1AF-473B-87C6-303094FCAEACQ40233944-B81AD90E-1E36-4CD4-A737-83C0E0D7A4C3Q40847170-F79369F0-8BA4-442D-A03C-604D6CD3A1BBQ42665889-86ACE62B-4206-4291-8FD9-67F5A7B7FA8BQ43714764-40A7CF7D-8BD8-4BD9-9AF8-7205DE05C350Q44053790-8CA15D11-4C8A-4D8D-B77C-6D36D6E18352Q44344480-B066094B-9047-4F52-A0CA-587976857FF7Q46093977-F88E6468-D178-4BBC-9BC0-A03166D2655CQ46206816-DFEC0D1A-6DBC-4D67-91BF-619AF69425AEQ46413245-77748CCC-45AD-4A5E-96BE-A9C1A2F1CF71Q46720102-10756B28-B40C-4EF5-8A38-6C4E85F42E1EQ47618059-68CFD28E-0B00-40C2-ACDE-17CAF2493945Q47622027-4F640AD1-E39B-461F-BC50-41994AD5FFD1Q47625326-2D8EBAE7-29EE-40EA-8C12-BBF100047745Q48273359-AEA3D31B-D8F1-440B-A6FF-34088A6CD058Q50654442-89EA33FB-B1E2-4293-8084-CF155304CA1CQ52658813-C937F56C-363C-4CF3-81DD-12AB13C57681Q52667522-603AD790-02C4-4557-9C2C-2476D317163A
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Sengwee Toh
@en
Sengwee Toh
@nl
type
label
Sengwee Toh
@en
Sengwee Toh
@nl
prefLabel
Sengwee Toh
@en
Sengwee Toh
@nl
P31
P496
0000-0002-5160-0810